NCT05266612View on ClinicalTrials.gov

Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 9, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Solid Tumor
Interventions
DRUG

VG2025

"1. 1.0×108PFU Day 1 and 15~2. 2.0×108PFU Day 1 and 15~3. 3.0×108PFU Day 1 and 15~4. 4.0×108PFU Day 1 and 15"

DRUG

Nivolumab Injection [Opdivo]

Flat dose of 240 mg every two weeks.

Trial Locations (2)

77030

RECRUITING

MD Anderson, Houston

85234

RECRUITING

Banner MD Anderson Cancer Center, Gilbert

All Listed Sponsors
lead

Virogin Biotech Canada Ltd

INDUSTRY